Semax

Semax is a synthetic heptapeptide analog of adrenocorticotropic hormone (ACTH), specifically derived from the ACTH(4-10) fragment, with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro. Developed in Russia, it exhibits pronounced nootropic, neuroprotective, and neurotrophic properties without hormonal activity. The peptide works through multiple mechanisms including modulation of brain-derived neurotrophic factor (BDNF) expression, enhancement of dopamine and serotonin levels, melanocortin receptor interaction, and anti-inflammatory effects. Research demonstrates efficacy in treating acute ischemic stroke, cognitive impairment, optic nerve diseases, and peptic ulcers. Clinical trials in Russia have shown improvements in neurological recovery, memory, attention, and neuroprotection. Semax is approved and marketed as a prescription medication in Russia and Eastern Europe, where it has been in clinical use since the 1990s. However, it has not been evaluated or approved by regulatory agencies in the United States, European Union, United Kingdom, or most other countries, where it is sold only as a research chemical.

Cognitive Enhancement

• Memory and Learning: Single intranasal application (50 μg/kg) increases hippocampal BDNF protein levels by 1.4-fold and trkB tyrosine phosphorylation by 1.6-fold, with treated animals showing enhanced conditioned avoidance learning ^[1][2]
• Attention and Focus: Improves selective attention and short-term memory in healthy humans at doses of 250-1000 μg/kg, with EEG changes similar to other neuroprotective drugs ^[3]
• Neurotrophin Modulation: Rapidly activates BDNF and NGF gene expression in hippocampus, frontal cortex, and other brain regions within 20 minutes to 24 hours post-administration ^[4][5]

Neuroprotection and Stroke Recovery

• Acute Ischemic Stroke: Clinical trial of 30 patients showed accelerated restoration of neurological functions, particularly motor deficits, when added to standard therapy (12-18 mg/day) ^[6]
• Functional Recovery: In 110 stroke patients, Semax administration increased plasma BDNF levels and enhanced functional recovery, especially when combined with early rehabilitation ^[7]
• Molecular Mechanisms: Suppresses inflammatory gene expression while activating neurotransmission genes, reduces phosphorylated JNK (pro-inflammatory) by 1.5-fold, and increases phosphorylated CREB (neuroprotective) in ischemic brain tissue ^[8][9]
• Immune and Vascular Modulation: Alters expression of 36 immune-related genes and 12-24 vascular system genes, promoting endothelial tissue development and reducing immune cell infiltration ^[10]

Alzheimer's Disease and Amyloid Protection

• Anti-Aggregation Effects: Prevents formation of amyloid-beta:copper complexes and inhibits fibril formation, reducing membrane damage and neurotoxicity by approximately 90% in cellular models ^[11]
• Copper Chelation: Forms stable complexes with copper(II) ions, preventing copper-induced cytotoxicity in neuroblastoma and endothelial cell lines ^[11]

Additional Therapeutic Applications

• Optic Nerve Diseases: Improves visual acuity, visual field extension, and optic nerve conductivity in vascular, toxic-allergic, and inflammatory optic nerve diseases; shows advantages over traditional neuroprotective treatment in glaucoma patients ^[12][13]
• Peptic Ulcer Healing: Combined with standard antiulcer medications, achieved 89.5% ulcer healing by day 14 versus 30.8% in controls among patients with refractory peptic ulcers ^[14]
• Anxiolytic Effects: Normalizes anxiety-related behavior in stressed animals without affecting normal emotional states, demonstrating selective anxiolytic action under pathological conditions

Clinical Safety Profile

• General Tolerability: Available clinical data reports that Semax is well tolerated with no specific adverse reactions or serious adverse events in intranasal or subcutaneous formulations documented in clinical or preclinical trials ^[1][6]
• Limited Safety Data: The available scientific data on long-term safety is scarce, with most clinical trials focusing on short-term administration (5-10 day courses). More research is needed to evaluate potential risks of prolonged use ^[1]
• Special Populations: Safety has not been evaluated in pregnancy or in patients with liver or kidney disease. Approximately 7.4% of diabetic patients showed mild increases in blood glucose levels during use ^[1]

Regulatory Status

• Russia and Eastern Europe: Approved as a prescription medication since the 1990s and listed on the Russian List of Vital & Essential Drugs (approved December 7, 2011) for conditions including ischemic stroke, optic nerve disease, and cognitive impairment ^[2][13]
• United States: Not approved by the FDA as a drug or dietary supplement; sold only as a research chemical labeled "not for human use." Legal to possess and purchase for research purposes but not approved for human consumption ^[2]
• European Union and UK: No authorization as a medicine; possession and sale fall under gray-market rules for unapproved compounds, with importation typically restricted unless labeled for laboratory research ^[2]
• International Status: Not approved or marketed in most countries outside Russia and Eastern Europe, including Australia ^[2]

Side Effects

• Intranasal Administration: Nasal irritation (burning sensation, congestion, or runny nose) is the most common side effect. Nasal cavity discoloration occurs in approximately 10% of patients ^[1]
• Neurological Effects: Mild and temporary headaches are commonly reported, though some users experience more severe or persistent headaches. Insomnia or sleep disturbances may occur due to enhanced alertness ^[1]
• Gastrointestinal: Mild, short-lived nausea has been reported ^[1]
• Other Effects: Transient dizziness or lightheadedness, possibly related to blood pressure or neurotransmitter changes. Some users report increased anxiety or restlessness, though Semax is also used to alleviate anxiety ^[1]
• Injectable Form: Potential local reactions including pain at injection site, skin irritation, redness, bleeding, swelling, and infections ^[1]

Research Gaps

• Long-Term Safety: Extensive long-term safety studies in humans are lacking, with most trials limited to short courses of 5-14 days ^[1]
• Standardized Dosing: Optimal dosing protocols for different conditions remain to be fully established through large-scale clinical trials ^[3]
• International Validation: Most published clinical research has been conducted in Russia, with limited English-language peer-reviewed trials and no FDA-approved clinical trials in Western countries ^[6][7]